Page last updated: 2024-08-26
paxilline and s 1033
paxilline has been researched along with s 1033 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barrett, A; Brandner, S; Evans, IM; Frankel, P; Frolov, A; Li, N; Lockwood, N; Paliashvili, K; Sidlauskas, K; Zachary, IC | 1 |
Other Studies
1 other study(ies) available for paxilline and s 1033
| Article | Year |
|---|---|
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Discoidin Domain Receptor 1; Focal Adhesion Kinase 1; Glioblastoma; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction | 2016 |